

Full Year Results 2023

5 March 2024





2023 Highlights

- 2023 was a challenging year for the Group
- Slower order intake as lead times and customer inventory levels normalised
- Revenue of £316m up 9% y-o-y at constant FX. Record level benefiting from shipping backlog
- Adjusted operating profit £38.1m, including higher product development amortisation and impairment charges booked at year-end
- Net debt reduced by 25% to £113m. Net debt/Adjusted EBITDA to 2.0x, following equity placing, strong operating cash conversion and reduced inventory offset by long term investments
- Record customer design wins in the year with strong sampling supporting medium term growth
- 11 new products launched, and strong growth delivered within focus areas such as high voltage/power categories
- FuG, acquired in 2022, is performing well with further growth potential
- Net Zero Transition Plan launched, targets approved by SBTi in February 2024, significant reduction in emissions in 2023





Key Performance Indicators 2023

Orders & Revenue

ORDER INTAKE **£208.8 million**Down -43%¹

REVENUE **£316.4 million** Up +9%¹

1: In Constant Currency2: Metrics excluding adjustments

Margin

GROSS MARGIN
41.5%
No Change

ADJUSTED
OPERATING MARGIN²
12.0%

Down -280bps

Profit & Earnings

ADJUSTED OPERATING PROFIT²

£38.1 million

Down - 3%1

ADJUSTED DILUTED EPS²

81.8p

Down -49%

Cash & Debt

ADJUSTED OPERATING CASH CONVERSION²

173%

Up from 42%

NET DEBT

£112.7 million

December 2022: £151.0 million



Income statement

2023		At actual exchange	In
	2022	rates	constant currency
316.4	290.4	9%	9%
131.3	120.6	9%	
1.5%	41.5%	-	
93.2)	(77.7)	(20)%	
38.1	42.9	(11)%	(3)%
2.0%	14.8%	(280)bps	
11.5)	(4.9)	(135)%	
26.6	38.0	(30)%	
(9.8)	(6.1)	(61)%	
16.8	31.9	(47)%	
31.8p	160 1n	(49)%	
	(9.8) 16.8	11.5) (4.9) 26.6 38.0 (9.8) (6.1) 16.8 31.9	11.5) (4.9) (135)% 26.6 38.0 (30)% (9.8) (6.1) (61)% 16.8 31.9 (47)%

- Healthy revenue growth, with all sectors benefiting from delivery of backlog
- Gross Margin maintained at 41.5%,
 protected from residual inflationary impacts
- Adjusted operating profit of £38.1m included £4.0m of amortisation and impairment charges booked at year-end. Underlying profit excluding these charges in line with expectations
- Finance cost driven by increased average debt and US interest rates during 2023
- Tax charge higher due to impact from treatment of tax losses in US



Order intake trends



Note: 2018-2022 restated at 2023 average FX rate

Order intake by quarter 2023 (£ million)




- Order intake normalising after unprecedented activity in 2021 and 2022
- Largest reduction in Semiconductor manufacturing, due to industry-wide cyclical slowdown
- Healthcare and Industrial Technology order intake slowed toward end of year:
 - Shorter delivery lead times allowed customers to order later
 - Indications of elevated customer inventory at year end, e.g.
 Healthcare intake reduced by 29% between Q3 and Q4
 - Customers focused on reducing working capital and buffer stock expected to be completed in H1 2024



Revenue trends – H1 vs H2

H1 growth bridge by Sector



- Growth of 9% for 2023 in total as stronger supply chain enabled delivery of order book. Growth driven equally from volume and price
- Particularly strong progress in H1:
 - Up 24% with all sectors growing
 - Slowdown in Semi orders not yet materially impacting revenue
 - FX gain due to weak Sterling


H2 growth bridge by Sector



- Pace of progress moderated in H2 as backlog unwound
- Tougher comparatives
- Industrial Technology and Healthcare sales continued to grow, supported by delivery of backlog
- Strong performance in H2 2022 combined with impact of Semi slowdown resulted in reduction



Order book trends




- Order book reduced by £116m to £192m in 2023
- Four main factors:
 - Increased shipments due to clearance of backlog
 - Reduced order intake due to shorter delivery lead times and overstocking
 - Some order cancellations in H1
 - Slowdown in activity levels in Semiconductor Manufacturing Equipment sector
- Order book remains above historic norms, but normalisation expected in H1 2024
- Book to bill at 0.66x



Adjusted Operating Profit bridge

Adjusted Operating Profit bridge



- Strong operating leverage from volume growth
- Residual input cost inflation passed through in pricing, maintaining gross margin at 41.5%
- Operating expenses includes cost inflation and increased variable pay. Overheads reduced in H2 following restructuring, with further actions taken in 2024
- Product development costs increased by £6.1m:
 - £2.5m increase in underlying expenditure for long-term growth
 - £1.9m write-down to capitalised costs – one off
 - £1.7m increase in ongoing amortisation of capitalised costs
- FX movement translational in nature, reflecting volatility in GBP:USD in 2022 and 2023



Free cash flow


Reported		
£ million	2023	2022
Adjusted Operating profit	38.1	42.9
Depreciation, amortisation & impairment	17.2	13.4
Adjusted EBITDA	55.3	56.3
Change in working capital	14.0	(33.5)
Other items	(6.9)	(22.8)
Operating cash flow	62.4	2.1
Net capex – product development costs	(9.5)	(8.0)
Net capex – other assets	(30.5)	(11.4)
Purchase of bond for Comet legal case	-	(36.9)
Net interest paid	(11.9)	(5.5)
Tax paid	(4.9)	(4.1)
Other items	(2.3)	(5.8)
Free cash flow	3.3	(69.6)

- Record operating cash flow of £62.4m, weighted toward H2 and driven by working capital reduction
- Working capital reduced by £1m in H1 and £13m in H2, reflecting successful efforts to reduce raw material inventory and work in progress
- Overall inventory reduced by £22.8m in the year to £91.6m with further reduction expected in 2024
- Physical capex of £30.5m included two new leased sites in California and construction of a new factory in Malaysia. Further £11m of residual cash spend on these projects in early 2024
- Malaysia commissioning deferred until end of 2025 in line with demand requirements
- Interest payments reflected level of debt and higher US interest rate in 2023



Net debt and leverage

Net debt bridge



Net debt/ Adjusted EBITDA

2.0x

£73m

Available liquidity

Dec 2022: 2.7x Dec 2022: £37m

Adjusted operating cashflow conversion

173%

2022: 42%

- Group started 2023 with elevated leverage due to various one-off factors
- Market slowdown and extra spend on major capex projects in H2 limited scope for leverage reduction
- Funding Plan launched in Q4 2023:
 - Ongoing cash focus benefitted H2
 - Cost reduction actions
 - Covenant amendments
 - Share placing
- Reduced leverage to 2.0x by year-end
- Ample liquidity in the business
- Leverage management remains our priority in 2024
- Pace of de-leveraging should increase from 2025 onwards



Funding Plan – update on actions

	Impact by 31 Dec 2024 (£m)		Dec 2024 (£m)	<u> </u>			
Action	Type	Net Debt	Annual EBITDA	Latest Status	Latest update		
Operating cost reduction	EBITDA improvement / Cash preservation	 £8-10 million	£8-10 million	l Done	 All actions taken Run-rate reduction achieved is in the middle of range Further actions being taken in Q1 2024 Expect to achieve significant overhead reduction in 2024 net of inflationary increases 		
Suspend dividend	Cash Preservation	£21.5 million		Done			
Inventory reduction	Debt Reduction	c.£10 million	-	Ahead of plan	 Inventory at time of Plan was £107 million Inventory at 31 December £92 million driven predominantly by actions in H1 Further optimisation expected in 2024 		
Capex minimisation	Cash Preservation	£10-15 million		Done			
Supplier payment term standardisation	Debt Reduction	£3.5 million	-	Underway	 c.50 suppliers identified with annual spend of c.\$30m 15% complete by end of 2023 Expect progress to accelerate in H1 2024 Taking longer, but potential upside greater 		
Total		£53-60 million	£8-10 million	I			



2024 Modelling Guidance

Profit:

- c.35:65 split of Adjusted operating profit between H1 and H2
- High single digit reduction in overheads
- c.25-30% effective tax rate (remaining elevated in 2024 whilst US tax structure is optimised)

Cash:

- Adjusted operating cash conversion > 100%
- Total capital spend including capitalised product development of c.£25m:
 - Including residual spend of £11m on 2023's major projects
- Assuming no currency impacts, debt to peak around mid-year
- Trading in line with expectations would leave net debt/ EBITDA at or below
 2.5x at year end





We have a clear strategy



Market leading product portfolio



Target & drive penetration in accounts where we can add value



Continually enhance our global supply chain



Focus on people and talent development



Lead our industry on environmental responsibility

Power XP Power long term fundamentals remain intact

High levels of "recurring" revenue due to designed in nature - Flexpower Configurable




Continued success with Customers



Long term relationships with key customers....with upside potential from driving wallet share



With ongoing strong operating cash





Overview: Industrial Technology

Overview


- XP focuses on subsectors within Industrial Technology with good, long term growth potential and attractive niches
- A broad sector with no notable customer concentration
- Includes distributors
- Resilient, long term, growth sector



Long term outlook

- Diverse sector with attractive overall growth outlook at 5.8%* per annum over the medium term
- Key trends driving demand include:
 - More products requiring connectivity and intelligence
 - Significant demand for technologies that enable electrification
 - Al era Smart mobility and manufacturing with Gen. Al leading the way
 - Demand for higher power capability
 - Smart manufacturing and warehousing
 - Analytical instrumentation growing interest in precision medicine & drug discovery

Revenue Split & Products



Industrial Technology

Subsectors:

- Analytical instrumentation
- Test and measurement
- Industrial printing
- Additive manufacturing
- Process control and automation
- Robotics





Overview: Semiconductor Manufacturing Equipment

Overview

An attractive growth opportunity for full portfolio of power products

- As post-pandemic demand for PCs, smartphones, and consumer electronics eased, Wafer Fabrication Equipment (WFE) spend slowed in 2023. Going forward expected to recover strongly to support end market demand
- Geopolitical factors & demand driving investments in semiconductor capacity
- XP has broad exposure across the processes and both leading and lagging edge technology




Semiconductor Revenue (@ CER 1 £m)

Long term outlook

Attractive long term growth outlook as semiconductors are the foundation of digitization and all technology advances

- End market expectations are for a 9% CAGR to 2030 taking the market to \$1 trillion per annum. WFE spend grows as fast or faster than semiconductors
- There are more than 100 Fabs* globally that are starting construction between 2022 and 2026 timeframe, 89 of these fabs have already either begun operation, equipping or construction. These will drive the major share for equipment spending by 2026
- XP well placed with the market leaders to grow ahead of the sector. Positioned for profitable growth as the market expands

Revenue Split & Products



Applications:

- Etch
- Deposition
- Lithography
- Ion implantation
- Test and inspection
- Wafer cleaning






Overview: Healthcare

Overview


- Regulatory and safety critical nature of the Healthcare sector means power is critical
- Advances in medical technology means supporting innovation
- Healthcare market need reliable power solutions



Long term outlook

- Medical device market forecast to grow at 7%* CAGR to \$800 bn by 2030 accelerating from 5% over last decade
- Growth driven by megatrends of ageing global population and innovation in medical technology
- Growth from robotic surgery and embedded devices, with more from incorporation of AI, medical imaging, minimally invasive procedures and patient treatment devices
- All require complex, reliable power solutions that meet strict regulatory requirements

Revenue Split & Products



Applications:


- Patient monitoring
- Surgical robotics
- Imaging and diagnostics
- Clinical lab instruments
- Home healthcare
- Patient treatment





Strategy in action: Product design and innovation

- Focus on anticipating future product trends/needs through close contact with our customers. We aim to create standard platform products that can be easily customized to solve specific customer power problems
- Our products add value to our customers through class leading power density, interconnectivity, efficiency and intelligence
- Customer value is created through application specific know how, working with them to solve power problems using technical capability and speed including rapid prototyping
- 8 Global R&D centres located close to customers and operations for closer collaboration (US, UK, Germany, Philippines & Singapore)
- >160 multi-disciplined team working in R&D and product design
 ~ 9% of revenue invested in R&D in 2023
- LV innovations focused on digital control / power, intelligence and efficiency. HV & RF focused on digital control, low noise, stability, repeatability and efficiency
- 11 new products launched in 2023 with full pipeline of products for 2024/5
 - Record new business wins up 7% YoY
 - Customer live project funnel, growing double double-digit







Strategy in action: Enabling growth & pace of innovation globally

- Keys to Success : Agility & Innovation Class leading local and Asian high volume manufacturing from prototype to full solution
 - Fast to Solve Have the right people and tools to solve challenges
 - Fast to Prototype Have the right infrastructure and customer engagement
 - Fast to HVM Seamless transition from prototype to production
- Continue to Invest and Innovate
 - XP global manufacturing sites (Business continuity and capacity focus)

	High Volume Mfg (HVM)			Small >> Medium Volume Mfg & NPD				
XP Mfg Site	XP China (Kunshan)	XP Vietnam (Binh Duong)	XP Malaysia (Seri Iskandar Perak)	XP RF (Gloucester MA)	XP HVHP (High Bridge NJ)	XP Guth (Salach DE)	XP FuG (Schechen DE)	XP San Jose (CA)
Product Capability Today/Future	LV, HVHP, RF	LV, HV, RF Customer Specific	LV, HV, RF Customer Specific	RF	HVHP	НУНР	НVНР	LV, HV, RF Customer Specific Including Prototypes



Strategy in action:

Leading the industry on sustainability





- Targets set in line with Science Based Targets initiative (SBTi)
 - Approved by SBTi in February 2024
- Net Zero Transition Plan published in August 2023
- CDP climate change score improved to "B"



- We continue to support our employees
 - Training and development
 - Promoting a fair working environment with equal opportunities
 - Mental health is a priority
- Through workforce engagement, views of our people are heard at board level
- Leading our industry in sustainability will bring significant benefits to XP Power

- We have updated XP Power's full carbon footprint including scope 3
 - Majority of emissions are outside of our operations – mostly from components we purchase and our products in use
 - Significant decrease v 2022 mainly from changes in product mix and reduced inventory
 - Purchased Renewable Energy Certificates (RECs) across global operations to reduce our scope 2 marketbased emissions to zero
 - Future product design and efficiency as well as supplier engagement key in driving down emissions
 - Critical that governments continue to rapidly decarbonise their electricity grids

XP Power Impact of Strategy Execution: Financial Framework



- Drivers of sales growth:
 - GDP & market growth
 - Record new business wins in 2022 and 2023
 - Strong sampling performance post COVID-19
 - Market leading NPD
- Drivers of Margin expansion:
 - Recovery and operational leverage with high drop through combined with moderating overhead investment
 - Cost and productivity focus
 - Production transfer "East"
- Cash Conversion:
 - Target 100% cash conversion
- ROCE:
 - Low capex model
 - Expansion capex directly linked to revenue growth
- Leverage:
 - Focus on reduction in short and medium term
 - Long term target reduced to 0-1x

^{1:} Adjusted operating cash flow (excluding Adjustments) divided by adjusted operating profit

^{2:} Adjusted operating profit divided by capital employed

^{3:} Net debt divided by Adjusted EBITDA



2024 and medium-term outlook

- Expect recovery in second half order intake with momentum into 2025
- Focusing on the controllables:
 - Execution of our strategic priorities
 - Preparing for customer "ramp", as little preparation time expected
 - Working capital improvement as inventory unwinds
- Expect net debt to increase at first half, before leverage reducing to at or below
 2.5x at year-end
- 2024 will be heavily second half weighted
- Excited about longer term growth opportunities supported by XP fundamentals, new design wins and new product pipeline









Market data a growing addressable market

Market (\$ Million)	Size	Share ¹
Asia	1,610	1.8%
Europe	813	14.6%
North America	1,258	14.1%
Total	3,681	8.8%
RF Power	2,102	1.7%
High power/high voltage	710	4.6%
Grand total	6,493	6.1%

XP 2023 Revenue (£ Million)	Asia	Europe	North America	Total	Share of XP (%)
Healthcare	6.6	26.8	44.5	77.9	25%
Industrial Technology	14.7	67.6	54.0	136.3	43%
Semi Fab	12.8	3.4	86.0	102.2	32%
Total	34.1	97.8	184.5	316.4	100%
Share of XP (%)	11%	31%	58%	100%	

Source: Micro-Tech Consultants (September 2023), VLSI Research (May 2023) and XP Power Management 1. Based on FY 2023 revenues



Competitive global manufacturing footprint



Adding Capacity in all production sites

- In all LV, RF and HV sites
- Added RF and HV manufacturing capability to China, diversifying from US
- 'Customer value add' in Vietnam





- Slowed down spend given current conditions
- Final capacity potential \$300-400m over long term
- To complement Vietnam and China
- Well connected, skilled labour, cost competitive







Strategy in action NPD: HP Series & HPF3K0 Launch

Customer Problem

- Customer requires dynamic control of the key elements of their application
- Meeting higher efficiency and reliability requirement to achieve sustainability and net-zero goals with relevant industry approvals

Market Demand: An attractive market subsegment

 >1500w power class growing 2x wider market, driven by higher power requirements in all segments

XP Solution

- HP Series launched in 2019, further expanded in 2023 with HPF3K0 launch
- 3kW AC-DC, scalable, digital, configurable platform
- Digital monitoring and control of the process and equipment, scalability and configurability with Semiconductor compliance, Healthcare and Industrial safety approvals
- >\$20m incremental revenue by 2023 and still in early stages of long-term growth
- Strong product pipeline across LV, HV & RF with new platform products expected to be launched in 2024



HPF3K0 Series



CT-Scanner is one of the products in medical imaging that has higher power AC-DC requirements for multiple applications.



Disclaimer



The information contained in this document is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this document or on its completeness, accuracy or fairness. The information in this document is subject to change.

This document contains statements about XP Power Limited that are or may be forward-looking statements. Forward-looking statements include statements relating to (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies and the expansion and growth of XP Power Limited's operations and potential synergies; and (iii) the effects of government regulation on business.

These forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of XP Power Limited. They involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person to be materially different from any results, performance or achievements expressed or implied by such statements. They are based on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate in the future. All subsequent oral or written forward-looking statements attributable to XP Power Limited or any of its shareholders or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included in this document speak only as of the date they were made and are based on information then available to XP Power Limited.

Investors should not place undue reliance on such

forward-looking statements, and XP Power Limited does not undertake any obligation to update publicly or revise any forward-looking statements.

This document does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to sell or issue, or any solicitation of any offer to buy or acquire any securities of XP Power Limited or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied upon, in connection with any contract or commitment or investment decision whatsoever. This document is not a prospectus or other offering document and does not purport to be allinclusive. The information contained in this document has not been independently verified by XP Power Limited or any other party. No representation or warranty, either express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reliability of the information contained herein. It should not be regarded by recipients as a substitute for the exercise of their own judgment.

This document is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration of licensing within such jurisdiction. The information contained in this document does not constitute a public offer under any applicable legislation, or an offer to sell or solicitation of an offer to buy any securities. This document shall not constitute an offer of securities for sale in the

United States.



POWERING THE WORLD'S CRITICAL SYSTEMS